Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.36 |
| ▸ | BCR | P11274 | 4/20 | 0.36 |
| ▸ | IDH1 | O75874 | 8/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488177 | 0.94 | ALOX5AP (0.38) | BRAFKITPDGFRAKDRNTRK1 | |
| SCHEMBL18960395 | 0.80 | NTRK1 (0.42) | NTRK1IDH1ITK | |
| SCHEMBL17488178 | 0.74 | NTRK1 (0.42) | NTRK1IDH1 | |
| SCHEMBL17488072 | 0.72 | CXCL8 (0.43) | BRAFKDRNTRK1ABL1BCR | |
| SCHEMBL17487511 | 0.67 | CXCL8 (0.53) | — | |
| SCHEMBL17488075 | 0.66 | KMT2A (0.52) | NTRK1IDH1 | |
| SCHEMBL17488071 | 0.66 | CXCL8 (0.42) | BRAFNTRK1ABL1BCRIDH1 | |
| SCHEMBL17488289 | 0.65 | IDH1 (0.46) | BRAFKDRNTRK1IDH1ITK | |
| SCHEMBL17487374 | 0.63 | MAPT (0.53) | — | |
| SCHEMBL17488202 | 0.63 | NOD1 (0.46) | NTRK1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | BRAF 3269/4885KIT 4107/4885PDGFRA 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.